Free Trial

15 Stocks That Insiders Won't Stop Buying - 14 of 15

 
 

Rezolute (NASDAQ:RZLT)

Dollar Amount of Shares Purchased
$4,171,890.31
Number of Insider Purchases in the Last 180 Days
8
Volume of Shares Purchased
1,280,405
Who Bought Shares
Brian Kenneth Roberts (Insider), Daron Evans (CFO), Nerissa Kreher (Director), Nevan C Elam (CEO), Wladimir Hogenhuis (Director) and Young-Jin Kim (Director)

Insider Trades by Quarter for Rezolute (NASDAQ:RZLT)

About Rezolute

Rezolute logoRezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. More about Rezolute
 
 

From Our Partners